Table 1.
The clinical characteristics of EGFR sensitive mutation group, control group and EGFR-TKIs treatment group.
| Category | Control group | EGFR sensitive mutation group | EGFR-TKIs treatment group | P value |
|---|---|---|---|---|
| Subjects (n) | 96 | 233 | 103 | |
| Age (years, median (P25th, P75th)) | 68 (63, 73) | 69 (59, 76) | 69 (57, 76) | 0.287 |
| Gender | 0.336 | |||
| Male (n, %) | 43 (44.8) | 91 (39.1) | 58 (56.3) | |
| Femal (n, %) | 53 (55.2) | 142 (60.9) | 45 (43.7) | |
| Smoking | 0.870 | |||
| Never (n, %) | 63 (65.6) | 150 (64.4) | 53 (51.5) | |
| Ex and current (n, %) | 33 (34.4) | 83 (35.6) | 50 (48.5) | |
| Clinical stage | ||||
| I–IIIA (n, %) | 130 (55.8) | 0 (0) | ||
| IIIB–IV (n, %) | 103 (44.2) | 103 (100) | ||
| Pathological type | ||||
| Squamous cell carcinoma (n, %) | 12 (5.2) | 5 (4.9) | ||
| Adenocarcinoma (n, %) | 220 (94.4) | 97 (94.2) | ||
| Adeno-squamous carcinoma (n, %) | 1 (0.4) | 1 (1.0) | ||
| EGFR sensitive mutation type | ||||
| 19del mutation (n, %) | 103 (44.2) | 51 (49.5) | ||
| L858R mutation (n, %) | 122 (52.4) | 49 (47.6) | ||
| Rare mutation (n, %) | 8 (3.4) | 3 (2.9) | ||
| EGFR-TKIs | ||||
| Gefitinib (n, %) | 31 (30.1) | |||
| Erlotinib (n, %) | 5 (4.9) | |||
| Icotinib (n, %) | 67 (65) | |||
P value for comparison between EGFR sensitive mutation group and control group.